Clinical Trial Update: Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 study (RENEGADE) evaluating Yttrium-90 radioembolization for early-stage renal cell carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Yttrium-90 radioembolization (yttrium-90 microspheres)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Stage I Renal Cell Cancer, Stage II Renal Cell Cancer | Phase 1, Phase 2 | Status: RECRUITING